Charles Grob is a Professor of Psychiatry & Biobehavioral Sciences and Pediatrics at UCLA. His work with MDMA was the first FDA approved Phase 1 study. He co-founded the Heffter Research Institute and is also affiliated with the Lundquist Institute for Biomedical Innovation.
Charles Grob got his BS in 1975 at the Columbia University, and his MD at the State University of New York in 1979. His work with psychedelics started in the early 2000s and has been a starting point of much more research into psychedelics.
He is also the editor of the book Hallucinogens: A reader, published in 2002.
- Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA (Mithoefer et al., 2016)
- MDMA-assisted therapy: a new treatment model for social anxiety in autistic adults (Danforth et al., 2016)
- Use of the classic hallucinogen psilocybin for treatment of existential distress associated with cancer (Grob et al., 2013)
- Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer (Grob et al., 2011)
- Pioneering Psychedelic Researcher Once Again Paves the Way with Historic Psilocybin Study for End of Life Patients (Lucid News, August 2020)
- Have A Good Trip (Netflix, May 2020)
- MDMA and Ayahuasca in Ritual and Therapy (Big Think, December 2019)
- Dr Charles Grob – Psilocybin at End of Life (Breaking Convention, 2013)
- Horizons 2012: CHARLES S. GROB, M.D. “Why Psychedelics Matter” (Horizons, 2012)
Explore more info with a membership (any level)
🧑 Extended profile information
📈 In-depth psychedelic reports (Sprout & Tree)
🪄 Weekly psychedelic research & implementation newsletter (free)